Marimed (MRMD) Asset Writedowns and Impairment (2020 - 2026)
Marimed's (MRMD) quarterly Asset Writedowns and Impairment came in at $76000.0 in Q1 2026, down 94.52% year-on-year from $1.4 million in Q1 2025, and up 26.67% on a QoQ basis from $60000.0 in Q4 2025.
Marimed (MRMD) Asset Writedowns and Impairment (2020 - 2026) Analysis & Trends
Marimed (MRMD) has 7 years of Asset Writedowns and Impairment data on file, last reported at $76000.0 in Q1 2026.
- On a quarterly basis, Asset Writedowns and Impairment fell 94.52% year-over-year to $76000.0 in Q1 2026; TTM through Mar 2026 was $270000.0, a 74.33% decrease from a year earlier, with the FY2025 full-year figure at $1.6 million, up 570.83% from the prior year.
- Asset Writedowns and Impairment for Q1 2026 stood at $76000.0, up from $60000.0 in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for MRMD reached as high as $1.4 million in Q1 2025 and fell as low as -$205000.0 in Q4 2024.
- Historically, Asset Writedowns and Impairment has averaged $174571.4 across 5 years, with a median of $39500.0 in 2022.
- On a YoY basis, Asset Writedowns and Impairment climbed as much as 6371.43% in 2023 and fell as far as 405.0% in 2023.
- Year by year, Asset Writedowns and Impairment stood at $40000.0 in 2022, then soared by 512.5% to $245000.0 in 2023, then plunged by 183.67% to -$205000.0 in 2024, then surged by 129.27% to $60000.0 in 2025, then gained by 26.67% to $76000.0 in 2026.
- Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $76000.0 in Q1 2026, $60000.0 in Q4 2025, and -$122000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Marimed | 23.85 Mn | 14.02 Mn | 15.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 76,000.00 |
| Mar 31, 2026 | 76,000.00 |
| Dec 31, 2025 | 60,000.00 |
| Dec 31, 2025 | 60,000.00 |
| Sep 30, 2025 | -122,000.00 |
| Sep 30, 2025 | -122,000.00 |
| Jun 30, 2025 | 256,000.00 |
| Jun 30, 2025 | 256,000.00 |
| Mar 31, 2025 | 1.39 Mn |
| Mar 31, 2025 | 1.39 Mn |
| Dec 31, 2024 | -205,000.00 |
| Dec 31, 2024 | -205,000.00 |
| Sep 30, 2024 | -116,000.00 |
| Sep 30, 2024 | -116,000.00 |
| Jun 30, 2024 | -15,000.00 |
| Jun 30, 2024 | -15,000.00 |
| Dec 31, 2023 | 245,000.00 |
| Dec 31, 2023 | 245,000.00 |
| Sep 30, 2023 | -122,000.00 |
| Sep 30, 2023 | -122,000.00 |